Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M142Revenue $M0.7Net Margin (%)0Z-Score0
Enterprise Value $M141EPS $0Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with PATH

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PATHMario Gabelli 2014-03-31 Sold Out $3.23 - $4.39
($4.06)
$ 4.255%Sold Out0
PATHRonald Muhlenkamp 2014-03-31 Sold Out -0.01%$3.23 - $4.39
($4.06)
$ 4.255%Sold Out0
PATHMario Gabelli 2013-12-31 Buy $1.62 - $3.39
($2.21)
$ 4.2592%New holding, 114500 sh.114,500
PATHRonald Muhlenkamp 2013-09-30 Add$2.39 - $2.91
($2.67)
$ 4.2559%Add 86.91%20,560
PATHRonald Muhlenkamp 2013-06-30 Buy 0.01%$2.67 - $3.66
($3.22)
$ 4.2532%New holding, 11000 sh.11,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PATH is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PATH Ronald Muhlenkamp 2014-03-310 0Sold Out
PATH Mario Gabelli 2014-03-310 0Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


PATH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BioAdvance Ventures L P10% Owner 2012-10-17Sell223,000$3.3526.87view
BVP GP LLC10% Owner 2010-08-11Buy293,590$10-57.5view
BV3 LLC 2010-08-11Buy27,066$10-57.5view
BV3 LLC 2010-08-11Buy54,758$10-57.5view

Press Releases about PATH :

    Quarterly/Annual Reports about PATH:

    News about PATH:

    Articles On GuruFocus.com
    Hedge Fund Billionaire Mario Gabelli´s Latest Positions Feb 21 2014 
    Possible Pay-Off for NuPathe Stock Holders Feb 17 2014 
    Special Situations Update: I Was Wrong on the NuPathe… Jan 29 2014 
    Special Situations Alert: Details Behind Why I Bought PATH Jan 28 2014 
    Thrifting for Billionaire Bargains 47% Off or More Since Gurus Bought Oct 21 2013 

    More From Other Websites
    NUPATHE INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of... Feb 21 2014
    Teva Completes Tender Offer for NuPathe Inc. Shares Feb 21 2014
    Special Situations Update: NuPathe Correction Jan 29 2014
    The NuPathe Contingent Value Right: Paying 25 Cents For A Dollar Jan 28 2014
    Special Situations Alert: Details Behind Why I Bought NuPathe Inc. Jan 28 2014
    Teva to Acquire NuPathe Jan 22 2014
    Teva (TEVA) Acquires NuPathe (PATH) for $144 Million Jan 21 2014
    NuPathe Picks Teva as Merger Partner Jan 21 2014
    Teva Expands CNS Specialty Business with Acquisition of NuPathe Jan 21 2014
    Teva to Acquire NuPathe for $144 Million, Outbidding Endo Jan 21 2014
    Teva buys NuPathe to expand central nervous system business Jan 21 2014
    NuPathe Terminates Agreement With Endo and Enters Into Agreement to Be Acquired by Teva Jan 21 2014
    NuPathe accepts Teva's takeover offer, ends deal with Endo Jan 21 2014
    Endo Merger Agreement with NuPathe Terminated Jan 21 2014
    NUPATHE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Jan 21 2014
    Endo Merger Agreement with NuPathe Terminated Jan 21 2014
    NuPathe Terminates Agreement With Endo and Enters Into Agreement to Be Acquired by Teva Jan 21 2014
    Teva Expands CNS Specialty Business with Acquisition of NuPathe Jan 21 2014
    NuPathe Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover Jan 17 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide